A Phase 1 Study of IMGN289 in Adult Patients With EGFR-positive Solid Tumors

Inclusion Criteria

• •18 years old at time of consent
• •Diagnosed with a solid tumor that has progressed despite standard therapy or for which no standard effective or curative options exist or are suitable
• •EGFR-positive tumor expression
• •Adequate blood and organ function
• •Must agree to use contraception while on study and for 12 weeks after the last dose of IMGN289 as applicable
• •Must be willing and able to sign informed consent and follow the study schedule and other protocol requirements